Page 4 - Evidence Development News Today

Medicare Part B will provide coverage for new amyloid-busting Alzheimer’s drugs as soon as the Food and Drug Administration grants traditional (full) approval, the Centers for Medicare & Medicaid Services announced Thursday morning. Coverage will require clinicians to participate in a patient data registry.

CMS in February 2023 announced 3 new models for testing by the Center for Medicare & Medicaid Innovation—all of which “aim to lower the cost of drugs, promote accessibility to life-changing drug therapies, and improve quality of care.”

MOULTRIE, Ga. — Alzheimer’s disease and other dementias are devastating. On Jan. 6, the U.S. Food and Drug Administration approved a medication that offers hope to those with Alzheimers.

On February 13-14, 2023, the Centers for Medicare & Medicaid Services (CMS) convened a virtual panel of the Medicare Evidence Development & Coverage…

The Centers for Medicare and Medicaid Services is not reconsidering the national coverage determination for Food and Drug Administration (FDA)-approved medications for Alzheimer's disease. The FDA-approved monoclonal antibodies are directed against amyloid, or the protein buildup, for the treatment of Alzheimer's disease. "We recognize that these medications are a unique, new

Upcoming Hearings - March 22 - Senate Committee on Health, Education, Labor and Pensions Hearing: “Taxpayers Paid Billions For It: So Why Would Moderna...

Equipped with the knowledge that the payer community has heavily restricted access to amyloid directed antibodies, Biogen and Eisai have elected to...

Lecanameb, the newly FDA approved drug, is likely to cost about $27,000 a year, according to various websites. While some with Mild Cognitive Impairment can afford the drug, most cannot. This inequity...

Crain's Health Pulse is your source for actionable, exclusive and inside news on the health care industry.

/PRNewswire/ -- The Alzheimers Association filed a formal request asking the Centers for Medicare & Medicaid Services (CMS) to provide full and unrestricted...